Home > Insider Trading > Filing (0001209191-23-024061)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070494	Acadia Pharmaceuticals Inc	ACAD	Pharmaceutical Preparations (2834)	061376651

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1816160	James Kihara	C/O Acadia Pharmaceuticals, Inc. 12830 El Camino Real, Suite 400 San Diego CA 92130	Principal Accounting Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-04-07	1,489	$0.00	5,720	No	4	M	Direct
Common Stock	Disposition	2023-04-10	523	$18.14	5,197	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-04-07	1,489	$0.00	1,489	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,489			No	4	M	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.14 to $18.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024.